Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Santhera grants Biovail rights to fipamezole; ends

Executive Summary

Days after acquiring fipamezole (JP1730) by exercising an option to take over the drug candidate's originator Juvantia, Swiss spec pharma Santhera is immediately monetizing the pharmaceutical asset, carving out US and Canadian rights to Biovail. Fipamezole has completed Phase II for levodopa-induced Parkinson's dyskinesia.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies